Hyperthermia and ablation system developer BSD Medical reported an increase in revenue for the first half of its 2013 fiscal year, due largely to the performance of its MicroThermX microwave ablation products for the treatment of cancer.
The company reported total revenue of $1.5 million for the first six months of fiscal 2013 (end-February 28), compared with $900,000 in 2012. Revenue for the second quarter of 2013 was $800,000, compared with $300,000 for the second quarter of 2012.
BSD posted a net loss of $1.9 million for the second quarter, compared with a net loss of $2.1 million for the second quarter of the previous year.
The company said it has a $800,000 backlog of hyperthermia product orders. This backlog does not include purchase orders from its exclusive distributor in Taiwan, Linden Bioscience.
